CathWorks has announced that the first patient has been enrolled in the Advancing cath lab results with FFRangio coronary physiology assessment—ALL-RISE—study.
The ALL-RISE study is a prospective randomised controlled trial (RCT) evaluating the clinical and economic benefits of the CathWorks FFRangio system for the diagnosis and treatment of coronary artery disease.
The study is expected to enrol 1,924 patients at up to 60 participating sites in North America, Asia, Europe and the Middle East. Patients presenting with coronary lesion(s) will be randomised to FFRangio-guided treatment or invasive pressure wire-guided treatment. While this is a global study, it will be the first RCT to assess outcomes of an angiography-based physiological assessment tool with patients enrolled in the USA, CathWorks said in a press release.
The ALL-RISE study is led by study chair, Ajay Kirtane (NewYork-Presbyterian/Columbia University Irving Medical Center, New York, USA) and Principal Investigators, William Fearon (Stanford University, Stanford, USA) and Allen Jeremias (St Francis Hospital & Heart Center, Roslyn, USA). The first patient was enrolled by Amir Kaki (Ascension St John Hospital, Detroit, USA).
“We have been utilising the FFRangio system for more than a year to better guide treatment decisions for patients with coronary artery disease and have adopted it as our physiology assessment tool of choice due to the safety and efficiency benefits it offers,” said Kaki. “We, at Ascension St John Hospital, are pleased to play a pivotal role in the ALL-RISE study and hope our findings will enable more physicians to experience the same benefits we have in our lab since adopting FFRangio.”
“The enrolment of the first patient in the ALL-RISE study marks an important step forward in our collective efforts to enhance precision-based medicine to optimise efficacy of coronary artery disease interventions,” said Martin Leon (Columbia University Irving Medical Center, New York, USA), chairman of the ALL-RISE executive committee. “We are grateful for the collaboration of leading institutions and clinical investigators around the globe who will be generating clinical and economic evidence that will shape the future of percutaneous coronary interventions.”
The FFRangio system combines artificial intelligence (AI) and advanced computational science to obtain quick and reliable FFRangio values from routine angiograms (X-rays), eliminating the need for drug stimulation and invasive pressure wires. The FFRangio system has the potential to enhance patient outcomes, improve workflow efficiency and reduce costs for healthcare systems, CathWorks said in a press release.
“We are incredibly excited to reach this significant milestone for CathWorks,” said Ramin Mousavi, president and chief executive officer of CathWorks. “The ALL-RISE study reinforces our commitment to advancing the interventional cardiology field by providing additional evidence to the clinical community on the potential impact of FFRangio in transforming patient care.”
In July 2022, CathWorks entered into a strategic partnership with Medtronic to amplify its efforts in bringing FFRangio to more physicians and patients globally.
“Through our partnership with CathWorks, we have been able to see first hand how this new, innovative technology helps to advance diagnosis, treatment and management of coronary artery disease,” said Jason Weidman, senior vice president and president of the Coronary and Renal Denervation Operating Unit at Medtronic. “We look forward to seeing how this important study adds to the existing evidence on the benefits of FFRangio and continues to drive adoption of the technology in clinical practice.”
